» Articles » PMID: 33172164

Genetic Variants of Lipoprotein Lipase and Regulatory Factors Associated with Alzheimer's Disease Risk

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Nov 11
PMID 33172164
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Lipoprotein lipase (LPL) is a key enzyme in lipid and lipoprotein metabolism. The canonical role of LPL involves the hydrolysis of triglyceride-rich lipoproteins for the provision of FFAs to metabolic tissues. However, LPL may also contribute to lipoprotein uptake by acting as a molecular bridge between lipoproteins and cell surface receptors. Recent studies have shown that LPL is abundantly expressed in the brain and predominantly expressed in the macrophages and microglia of the human and murine brain. Moreover, recent findings suggest that LPL plays a direct role in microglial function, metabolism, and phagocytosis of extracellular factors such as amyloid- beta (Aβ). Although the precise function of LPL in the brain remains to be determined, several studies have implicated LPL variants in Alzheimer's disease (AD) risk. For example, while mutations shown to have a deleterious effect on LPL function and expression (e.g., N291S, , and have been associated with increased AD risk, a mutation associated with increased bridging function (S447X) may be protective against AD. Recent studies have also shown that genetic variants in endogenous LPL activators (ApoC-II) and inhibitors (ApoC-III) can increase and decrease AD risk, respectively, consistent with the notion that LPL may play a protective role in AD pathogenesis. Here, we review recent advances in our understanding of LPL structure and function, which largely point to a protective role of functional LPL in AD neuropathogenesis.

Citing Articles

A Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease.

Sharma C, Mazumder A Cent Nerv Syst Agents Med Chem. 2024; 24(1):45-56.

PMID: 38305393 DOI: 10.2174/0118715249263300231116062740.


Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux.

Gugliucci A J Clin Med. 2023; 12(13).

PMID: 37445434 PMC: 10342861. DOI: 10.3390/jcm12134399.


Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.

Ferrer I Free Neuropathol. 2023; 3.

PMID: 37284149 PMC: 10209894. DOI: 10.17879/freeneuropathology-2022-3806.


Microglial metabolic reconfiguration provides a new strategy for the treatment of Alzheimer's disease.

Leng L, Zhang J Neural Regen Res. 2023; 18(9):1946-1947.

PMID: 36926714 PMC: 10233783. DOI: 10.4103/1673-5374.367842.


The influence of LPL S447X variants and obesity on lipid profile, oxidative stress, and the risk of T2DM: A case-control study.

Ahmed G, Rahimi Z, Kohsari M, Shakiba E Health Sci Rep. 2023; 6(1):e1031.

PMID: 36605456 PMC: 9808153. DOI: 10.1002/hsr2.1031.


References
1.
Raghavan N, Brickman A, Andrews H, Manly J, Schupf N, Lantigua R . Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease. Ann Clin Transl Neurol. 2018; 5(7):832-842. PMC: 6043775. DOI: 10.1002/acn3.582. View

2.
Doolittle M, Ehrhardt N, Peterfy M . Lipase maturation factor 1: structure and role in lipase folding and assembly. Curr Opin Lipidol. 2010; 21(3):198-203. PMC: 3924775. DOI: 10.1097/MOL.0b013e32833854c0. View

3.
Baum L, Wiebusch H, Pang C . Roles for lipoprotein lipase in Alzheimer's disease: an association study. Microsc Res Tech. 2000; 50(4):291-6. DOI: 10.1002/1097-0029(20000815)50:4<291::AID-JEMT8>3.0.CO;2-L. View

4.
Page S, Judson A, Melford K, Bensadoun A . Interaction of lipoprotein lipase and receptor-associated protein. J Biol Chem. 2006; 281(20):13931-8. DOI: 10.1074/jbc.M600995200. View

5.
Verheijen J, Van den Bossche T, van der Zee J, Engelborghs S, Sanchez-Valle R, Llado A . A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. Acta Neuropathol. 2016; 132(2):213-224. PMC: 4947104. DOI: 10.1007/s00401-016-1566-9. View